BioSpace News Archive

Lobe Sciences Ltd., a biopharmaceutical company focused on developing transformative medicines to treat rare diseases announced that Wesley Ramjeet has agreed to join its Board of Directors in the coming months.

EDAP TMS SA, the global leader in robotic energy-based therapies, announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company’s European and Middle Eastern commercial leadership.

Keros Therapeutics, Inc. today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Healthcare Conference on Monday, June 10, 2024 at 2:40 p.m. Eastern time.

4D Molecular Therapeutics today announced that management will participate in fireside chats at upcoming investor conferences in June.

Replimune Group, Inc. today presented two oral presentations highlighting promising clinical data from its RP1 and RP2 programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4 in Chicago.

Corcept Therapeutics Incorporated today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome).

Denali Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.

Entera Bio Ltd. today announced Phase 1 clinical data for its hypoparathyroidism focused investigational program, EB612, as presented on June 1st at the Endocrine Society ENDO 2024 Annual Meeting.

BriaCell Therapeutics Corp. announces positive clinical efficacy data updates of its ongoing randomized Phase 2 study evaluating lead clinical candidate Bria-IMT™ in patients with advanced metastatic breast cancer.

Medicenna Therapeutics Corp. presented updated clinical results highlighting significant survival benefit versus a propensity score balanced EC arm, in the Phase 2b Study of bizaxofusp (aka MDNA55; an Empowered Superkine targeting the IL-4R) in unresectable rGBM at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, IL, on June 1st, 2024.